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Glomerular deposition of cross—linked fibrin in human kidney diseases.
The immunofluorescent localization of cross—linked fibrin (XFb) in
kidneys from 87 patients with renal diseases was evaluated using a
monoclonal antibody that discriminates XFb from fibrinogen and its
derivatives. Glomerular deposition of XFb, along the endothelial sur-
face and in the mesangium, was frequently observed in patients with
IgA nephropathy, Henoch—SchOnlein purpura nephritis (HSPN), lupus
nephritis, and hemolytic uremic syndrome (HUS), which was con-
firmed by immunoetectron microscopy. Dual—label immunofluorescent
studies showed that XFb was deposited in limited areas among the sites
reactive with anti-fibrinogen antibodies; XFb was not present in the
crescents, Bowman's capsule or interstitium. The localization of XFb
was generally discordant with that of the platelet membrane antigen and
von Willebrand factor (factor Vill-related) antigen. Subendothelial
co-deposition of XFb and immunoglobulins (IgA with or without IgG)
occasionally accompanying C3 was found in the glomeruli of some of
the patients with IgA nephropathy and HSPN. The distribution of XFb
observed by immunoelectron microscopy was similar to that of electron
dense deposits. The glomerular population of monocytes/macrophages
in patients with XFb deposition was similar to that of those without
deposition. Urinary XFb derivatives were detected by the latex agglu-
tination test in three of the 16 patients with glomerular XFb deposition,
and in two of the 18 patients without it. These data indicate that the
coagulation system is activated in the kidney of patients with IgA
nephropathy, HSPN, lupus nephritis and HUS, and support the con-
cept that glomerular fibrin deposition is associated with endothelial!
subendothelial and mesangial injury. The activation of the coagulation
system in IgA nephropathy and HSPN seems to be mediated by
immune complexes rather than monocytes/macrophages. Determina-
tion of urinary XFb derivatives is not helpful for assessing glomerular
XFb deposition.
Several recent studies suggest that intraglomerular coagula-
tion plays an important role in the development of experimental
and human glomerulonephritis [1—31. Deposition of flbrinogen/
fibrin related antigen (FRA), platelets [4, 5] and various coag-
ulation factors, including factor VIII [6, 7], Hageman factor [8,
9] and factor XIII [10], were concordantly or discordantly
identified in the kidney tissues using immunohistochemical
techniques. The association between the amount of FRA de-
posits and the extent of histologic damage in the glomeruli has
been suggested [11]. In experimental nephritis, defibrination
with Ancrod decreases the severity of glomerular injury as well
as the number of crescents [12, 13]. Urinary FRA may reflect
the FRA deposition in the kidney [14].
FRA deposition in the kidney is thought to be suggestive of
intra-renal coagulation. However, FRA could be derived from
either fibrinogen, fibrin or their degradation products (collec-
tively termed FRA), because polyclonal antibodies that cross—
react with any of the above are routinely used. Therefore, it is
necessary to determine whether FRA are indicative of local
activation of the coagulation system, as discussed previously
[15, 161. Precise characterization of the FRA deposited in the
glomeruli or crescents is essential for a better understanding of
the nature of these lesions.
We demonstrated the deposition of cross—linked fibrin (XFb)
on the kidney tissues from patients with renal diseases using a
mouse monoclonal antibody that reacts with XFb and its
derivatives, but not with fibrinogen or its degradation products.
Furthermore, we studied the association of intraglomerular
XFb with the deposition of immunoglobulins, the infiltration of
immune cells and urinary excretion of XFb derivatives.
Methods
Source of tissues
Kidney tissues obtained by percutaneous needle biopsy or
surgical biopsy from 87 patients with different diseases were
used in the study: 34 patients with IgA nephropathy, 10 with
mesangial proliferative (non-IgA) glomerulonephritis, 17 with
Henoch—Schönlein purpura nephntis (HSPN), seven with idio-
pathic nephrotic syndrome with minimal change, three with
nephrotic syndrome with focal glomerular sclerosis, four with
membranous nephropathy, one with type I and two with type II
membranoproliferative glomerulonephntis (MPGN), five with
lupus nephritis, one with acute post-streptococcal glomerulo-
nephritis (AGN), and three with hemolytic uremic syndrome
(HUS). Three other kidney specimens were obtained from
patients with renal calculi or renal tumors in the course of
surgical management, and histologically normal portions were
used as normal kidney tissue.
Antibodies
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Monoclonal antibodies used in this study were: XFb,
DD-3B6/22 (mouse IgG, MAbCO, Brisbane, Australia) [17, 18];
von Willebrand factor (factor Vill-related) antigen (vWf:Ag),
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anti-vWf:Ag (mouse IgG, Cappel, Malvern, Pennsylvania,
USA); and platelets, anti-platelet membrane glycoprotein lIb
lila (mouse IgG, Immunotech, Marseille, France). Fluorescein
(FITC)-conjugated monospecific goat antisera to human fibrin-
ogen, IgG, IgA, 1gM, C3, C4 and Clq (Cappel) were used for the
direct method and for the dual—staining.
Infiltrating immune cells were identified with the following
monoclonal antibodies: all T-cells; T1B (mouse IgG2a, Coulter,
Hialeah, Florida, USA), helper/inducer T-cells; T4 (IgG1,
Coulter), cytotoxic/suppressor T-cells; T8 (IgG1, Coulter), B-
cells; Leu 12 (IgG1, Becton—Dickinson, Mountain View, Cali-
fornia, USA), and monocytes/macrophages; Mo2 (1gM, Coul-
ter) [19]. Polymorphonuclear cells (PMN) were stained with
FITC-conjugated anti-human lactoferrin (Cappel) [201.
Specificity of monoclonal antibodies
The reactivity of mouse monoclonal antibody DD-3B6/22 was
checked by enzyme—linked immunoassay (ELISA); fibrinogen,
XFb and their degradation products were prepared as described
previously [21—23]. Fibrinogen (grade L, Kabi, Molndal, Swe-
den) was purified with the gel filtration on Sephadex G-200
(Pharmacia, Uppsala, Sweden). Fibrinogen degradation prod-
ucts (X, Y, D and E) were prepared by the lysis of fibrinogen
with plasmin (Dai-ichi Pharmaceutical Co., Tokyo, Japan).
Early (X and Y) and late (D and E) products were obtained by
terminating the reaction with aprotinin (Bayer, Leverkusen,
West Germany) at 10 minutes and at 16 hours, respectively.
Early and late degradation products of XFb were prepared by
the incubation of fibrinogen with factor XIII (Behring
Marburg—Lahn, FRG), thrombin (Green Cross, Osaka, Japan)
and plasmin for 10 minutes and 16 hours, respectively. D-dimer
was purified by the gel filtration of late degradation products of
XFb on Sephadex G-200, as reported previously [22—231. Pro-
tein concentration was measured by dye—binding assay [24].
ELISA was performed essentially as described elsewhere [25,
261. The reaction was enhanced using avidin—biotin system.
Microtiter plates were coated at 4°C overnight with anitgens
(fibrinogen, D-dimer and degradation products of fibrinogen and
XFb) in 0.05 M carbonate buffer (pH 9.6). After washing with
0.15 M NaCI1O.05% Tween 20 (Sigma, St. Louis, Missouri,
USA), DD-3B6/22 (1:20 dilution in PBS/O.05% Tween 20) was
incubated at room temperature for one hour. This was followed
by the addition of biotin—conjugated affinity—purified goat anti-
mouse IgG (Cappel) diluted 1: 1000 in PBS/Tween 20 with 0.2%
bovine serum albumin (BSA). After incubation at room temper-
ature for one hour and washing, avidin—peroxidase conjugate
(Zymed Laboratories, San Francisco, California, USA) diluted
1:1000 in PBS/Tween 20 with BSA was added and incubated for
one hour at room temperature. Absorbance at 414 nm was
measured five minutes after the addition of the substrate,
2,2'-azino-di(3-ethylbenzoline sulfonic acid-6) ammonium salt
(ABTS) with 0.03% hydrogen peroxide. This monoclonal anti-
body clearly reacted with late degradation products of XFb and
purified D-dimer, and weakly reacted with early degradation
products of XFb (Fig. 1). There was no binding to fibrinogen or
its degradation products at the concentration up to 10 jig/ml,
which confirmed the observation by Whitaker et a! [17, 18]. The
antibody stained intraluminal clots in the capillaries of normal
human placenta at the dilution up to 1: 100 by indirect im-
munofluorescence.
The monoclonal antibody to platelet membrane glycoprotein
lib lila reacted with the surface of the platelet by indirect
immunoelectron microscopy. The staining was completely in-
hibited by the prior absorption of the antibody with platelets.
No reactivity was observed with monocytes, lymphocytes,
PMN and erythrocytes.
Mo2 was expressed by monocytes and cultured macrophages
by indirect immunofluorescence. There was no reactivity with
lymphocytes, PMN or erythrocytes.
Immunofluorescent studies
Specimens for immunofluorescence were snap—frozen in
isopentane precooled in liquid nitrogen or in dry ice and
acetone, and stored at —70°C until use. Immunofluorescent
staining was performed as follows: tissue samples were sec-
tioned into a thickness of 4 m on a cryostat. After air drying,
sections were fixed in acetone for five minutes at 4°C, washed in
PBS, and then stained using the direct and indirect methods, as
described previously [25]. In the direct staining, the sections
were reacted with FITC-labeled antibodies for 45 minutes at
room temperature. In the indirect staining, tissues were firstly
incubated with the optimally—diluted primary antibodies for 45
minutes at room temperature. After washing in PBS, the
sections were incubated with the appropriate secondary anti-
bodies, affinity purified F(ab')2 goat anti-mouse IgG or 1gM
(Cappel), coupled with FITC for 45 minutes at room tempera-
ture. Dual—label studies were carried out with FITC-labe!ed
goat antisera to human fibrinogen, IgG, IgA, and C3, followed
by monoclonal antibody to XFb and rhodamin (TRIC)-conju-
gated goat anti-mouse IgG (Cappel).
The double fluorochrome layer described by Platt et al [27,
28] was applied to identify immune cells; the kidney sections
were sequentially reacted with a monoclonal antibody (mouse
IgG or 1gM), FITC-labeled F(ab')2 goat anti-mouse IgG or 1gM
(Cappel), FITC-labeled F(ab')2 rabbit anti-goat IgG (Cappel),
and ethidium bromide (10 p.g/ml PBS) to stain the nuclei.
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Fig. 1. Avidin—biotin ELISA data showing DD-3B6/22 monoclonal
antibody reactivity with fibrinogen (0), purified D-dimer (•), early (0)
and late (U) degradation products offibrinogen (FgDP), and early (Lx)
and late (A) degradation products of cross—linked flbrin (XFbDP).
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Table 1. Immunofluorescent identification of fibrinogen/fibrin related antigen (FRA), cross—linked fibrin (XFb) and platelet membrane antigen
in the kidney, and detection of XFb derivatives in the urine
Disease
Total number
of patients
Glomerular deposition'
Urinary XFb"
Glomerular XFb
(+) (—)FRA XFb Platelet
IgA nephropathy 34 31 18 13 2/9 1/6
Mesangial proliferative (non-IgA)
glomerulonephritis 10 5 0 3 0/3
Henoch—SchOnlein purpura nephntis 17 17 12 6 1/5 1/1
Minimal change nephrotic syndrome 7 1 0 0 0/3
Focal glomerular sclerosis 3 2 0 0 0/1
Membranous nephropathy 4 2 0 0 0/2
Membranoproliferative glomerulonephritis 3 2 0 0 0/2
Lupus nephritis 5 5 5 4 0/1
Acute poststreptococcal glomerulonephritis 1 1 1 0
Hemolytic uremic syndrome 3 3 3 3 0/1
Total 87 69 39 29 3/16 2/18
a Numberof patients demonstrating positive immunofluorescence
ID Number of patients with urinary XFb derivatives/number of patients tested
After staining, the sections were mounted with p-phenylene—
diamine to retard fluorescence fading [29], and examined by
immunofluorescent microscopy (Optiphoto X, Nicon, Tokyo,
Japan), or by phase contrast—immunofluorescent microscopy
(HF-2, Olympus, Tokyo, Japan).
Standardization of monoclonal antibodies and controls
The appropriate dilution of the monoclonal reagents was
determined on frozen sections of normal human kidney, human
placenta, platelets, and tonsils. Secondary antibodies and ter-
tiary antibodies were preabsorbed with normal human plasma.
Control sections were reacted with FITC-labeled goat anti-
mouse IgG or 1gM, or TRIC-labeled goat anti-mouse IgG with
or without prior application of appropriate mouse monoclonal
IgG and 1gM antibodies.
Enumeration of immune cell population in tissue
Sections were examined under an immunofluorescent micro-
scope equipped with an ocular index grid. The number of
reactive glomerular cells and total glomerular cells (excluding
parietal epithelium) was determined as described by Platt et a!
[27, 28]. These data were expressed as positive cells per 100
glomerular cells. In each of the 10 to 20 fields per sections, the
number of reactive interstitial cells and total cells (excluding
glomeruli and arteries) were counted, and the percent of posi-
tive cells was calculated for each section. Statistical analysis
was done using Student's t-test.
Electron microscopy
A portion of the kidney tissue was fixed in 2% glutaral-
dehyde, washed in PBS, and postfixed in 1% osmic acid.
Ultrathin sections were cut and stained with lead citrate and
uranyl acetate. The grids were examined in a Hitachi HU-12A
(Tokyo, Japan) electron microscope.
Immunoelectron microscopy
Kidney tissues from patients with IgA nephropathy and
HSPN were examined by indirect immunoelectron microscopy
to localize the XFb deposits. The tissues were fixed in
paraformaldehyde—lysine--periodate fixative of McLean and
Nakane [30], and progressively treated with 10% sucrose in
PBS overnight, with 15% sucrose in PBS overnight, with 20%
sucrose in PBS overnight, and then embedded in OCT com-
pound [31]. The specimens were cut into 4 pm sections on a
cryostat, and placed on albumin—coated slides. After air drying,
the specimens were treated with a 5 m aqueous solution of
periodite (pH 2.5), followed by the incubation in a 3 mM
aqueous solution of sodium boron hydroxide to inhibit endog-
enous peroxidase, and incubated with the primary antibody
(mouse monoclonal antibody to XFb) at 4°C overnight in a
moist chamber. The tissues were then washed in PBS and
treated with the secondary antibody, affinity purified F(ab')2
goat anti-mouse IgG labeled with peroxidase (Cappel), at room
temperature for 45 minutes. They were fixed with 1% glutaral-
dehide/PBS for 10 minutes, immersed in the substrate solution
(20 mg diaminobenzidine HCII100 ml of 0.5 M Tris-HC1 buffer,
pH 7.6) containing 1% dimethylsulfoxide. After further incuba-
tion with diaminobenzidine solution containing 0.005% hydro-
gen peroxide for five minutes, the specimens were fixed with
2% osmic acid/PBS for two hours, and embedded in Epon 812.
After preparing ultrathin sections, these specimens were ob-
served under an electron microscopy without staining.
Determination of urinary XFb derivatives
Urinary XFb derivatives were measured using a latex—ag-
glutination test (Dimer test, MAbCO). Twenty—four—hour urine
samples were collected on the day before the renal biopsy, and
used for the determination. The sensitivity of this assay was 200
ng/ml of D-dimer. XFb derivatives were not detected in any of
the urine samples obtained from ten normal individuals.
Results
A total of 87 kidney tissues from patients with a variety of
renal diseases were examined using immunofluorescence for
XFb (Table 1). XFb was frequently observed in patients with
IgA nephropathy (18 of 34 patients, 53%), HSPN (12 of 17,
71%), lupus nephritis (5 of 5, 100%) and HUS (3 of 3). By the
use of combined phase and fluorescence microscopy, XFb was
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present within the glomeruli, along the endothelial surface of
the glomerular capillary and in the mesangium in these patients
(Fig. 2). In addition, XFb was deposited along the intima of the
arterioles in all patients with lupus nephritis and HUS, and in
some patients with IgA nephropathy and HSPN. There was no
detectable immunofluorescence with the normal kidney, or
kidney tissues from patients with mesangial proliferative (non-
IgA) glomerulonephritis, minimal change nephrotic syndrome,
focal glomerular sclerosis, membranous nephropathy and
MPGN. By dual—staining of the same section with anti-FRA
(FITC) followed by anti-XFb and anti-mouse IgG (TRIC), XFb
was detected at the sites that reacted with antisera to FRA (Fig.
2A and B). However, XFb showed a more restricted distribu-
tion than FRA; FRA was frequently positive in crescents,
Bowman's capsule and interstitium, while XFb was negative in
these loci. XFb was not found in 30 of the 69 patients (43%) with
glomerular FRA deposits (Fig. 2C and D).
The localization of platelets and vWf:Ag was compared with
that of XFb in the 87 patients. Granular deposits of platelet
membrane antigen were observed along the glomerular capil-
lary walls and the arterioles (Fig. 2E). Finely granular staining
for vWf;Ag was present along the glomerular endothelium and
arterioles of the normal kidneys, more intensely in these loci
and occasionally in the mesangium of kidney tissues from 13
patients with IgA nephropathy, nine with HSPN and four with
lupus nephritis (Fig. 2F). Glomerular deposits of XFb and
platelets accompanying increased intensity of immunofluores-
cence for vWf:Ag were found in 16 of the 87 patients. On the
serial slices of the specimens, the distribution of XFb was
discordant with that of the platelets and vWF:Ag in the
glomeruli, and concordant with that in the arterioles.
The localization of XFb was compared with that of immuno-
globulins (IgG and IgA) and complement (C3) in 11 patients (7
patients with IgA nephropathy and 4 with HSPN) determined
by the dual—staining method (Fig. 3). In six of them, XFb and
immunoglobulins were deposited at the same loci; four patients
(3 patients with IgA nephropathy and 1 with HSPN) showed
deposition of XFb with IgG and IgA, and two patients with IgA
nephropathy had deposition of XFb with IgA. The co-deposi-
tion was occasionally accompanied by C3, and was more
prominent along the glomerular capillary walls than in the
mesangial area.
Kidney tissues from eight patients (5 patients with IgA
nephropathy and 3 with HSPN) were studied by immunoelec-
tron microscopy, which confirmed the immunofluorescent find-
ings mentioned above (Fig. 4A). Indirect peroxidase staining for
XFb was positive beneath the glomerular endothelial cells and
within the mesangial matrix. Conventional transmission elec-
tron microscopy of the renal tissues from these patients re-
vealed that the localization of electron—dense deposits was
similar to that of the peroxidase—positive sites observed on
immunoelectron microscopy (Fig. 413). Fibrillar fibrin with
characteristic periodicity or translucent subendothelial areas
were rarely observed.
The association between XFb deposition and infiltration of
immune cells was investigated in 37 patients, including 16
patients with IgA nephropathy, 12 with HSPN, six with mesan-
gial proliferative (non-IgA) glomerulonephritis, one with mini-
mal change nephrotic syndrome, one with AGN, and one with
HUS (Fig. 5); glomerular XFb was present in 16 patients (8
patients with IgA nephropathy, 6 with HSPN, and patients with
AGN and HUS), and not present in the remaining 21 patients.
The population of glomerular cells reactive with Mo2
(monocytes/macrophages) was higher, though not significantly,
in the patients with XFb deposition (N = 16, mean SD, 2.83
6.90) than in those without XFb deposition (N = 21, mean
SD, 0.78 0.55; (Fig. 6). In both categories of the disease (IgA
nephropathy and HSPN), the glomerular population of
monocytes in the patients with XFb deposition was not signif-
icantly different from that in those without XFb deposition.
Significantly more monocytes infiltrated the glomeruli in pa-
tients with IgA nephropathy and HSPN than in those with
mesangial proliferative (non-IgA) glomerulonephritis (P <
0.05). T and B lymphocytes, and PMN, which rarely infiltrated
the glomeruli of patients with IgA nephropathy, HSPN and
mesangial proliferative (non-IgA) glomerulonephritis, were sim-
ilar in both groups. The relative proportion of interstitial cells
identified by the monoclonal antibodies and by the anti-lacto-
ferrin antibody did not significantly differ between the two
groups.
Urinary XFb derivatives were determined in 34 patients using
the latex—agglutination test (Table 1); glomerular XFb deposits
were present in 16 patients. XFb derivatives were detected in
the urine of five of the 34 patients (3 of the 16 with XFb
deposition and 2 of the 18 without it).
Discussion
The presence of fibrin is conventionally demonstrated by
histological staining, immunofluorescence or electron micros-
copy. Histological staining with dyes has proven too insensitive
and of doubtful specificity [32, 33]. Immunofluorescence with
anti-fibrinogen serum is sensitive enough to detect fibrin but
cannot discriminate fibrin from fibrinogen [1, 16]. Transmis-
sion electron microscopy allows the detection and accurate
localization of small amounts of fibrin. However, the charac-
teristic periodicity of polymeric fibrin is not always seen.
Rather, amorphous electron—dense materials are more com-
monly observed [2, 34].
Whitaker and his coworkers [17, 18] recently developed a
mouse monoclonal antibody that distinguished XFb and its
derivatives from fibrinogen or its degradation products, which
was confirmed by our ELISA data. Using this antibody, we
demonstrated glomerular XFb deposition in patients with IgA
nephropathy, HSPN, lupus nephritis, AGN and HUS, which
provides direct evidence for local activation of the coagulation
system, although it is indistinguishable whether the materials
detected by the antibody are fibrin proper or its degradative
form. Phase—fluorescence microscopy revealed the presence of
XFb along the endothelial surface of the glomerular capillary
and in the mesangium. This was in accordance with the immu-
noelectron microscopic observations. We found that XFb was
deposited in the kidney infrequently and less diffusely than
FRA. Among the sites reactive with anti-fibrinogen serum, XFb
was present along the glomerular capillary walls, in the mesan-
gium, and in the blood vessels, but it was not present in the
crescents, Bowman's capsule or interstitium.
FRA deposition without XFb was frequently observed in the
glomeruli of patients with mesangial proliferative (non-IgA)
nephritis, focal glomerular sclerosis, membranous nephropathy
and MPGN, suggesting that the coagulation system is not
Fig. 2. Immunofluorescence on kidney sections showing the localization of FRA, XFb, platelet membrane antigen and vWf:Ag, Dual—label
techniques with anti.FRA (FITC) and anti-XFb (TRIC) were used in A—D. IgA nephropathy: (A) FRA deposition in glomerulus, Bowman's capsule
and interstitium (xl ,450). (B) The same glomerulus showing XFb deposition along the glomerular capillary walls and in the mesangium. The
distribution was similar to that of FRA, but XFb was not present in Bowman's capsule or interstitium (x 1,450). Focal glomerular sclerosis: (C)
Intense FRA deposition in the glomerulus (x650). (D) No deposition of XFb in the same glomerulus (x650). igA nephropathy: (E) Platelet
membrane antigen deposition along the glomerular capillary walls (x 1,200). (F) vWf:Ag deposition in the glomerulus and along the wall of the
arteriole (arrow) (x650). G: glomerulus.
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Fig. 3. Dual—staining for immunoglobulins (!gG and IgA) (FITC) and XFb (TRIC). IgA nephropathy: (A) Intense IgG deposition in the glomerulus
(mainly along the capillary walls) (xl,330). (B) The same glomerulus showing similar localization of XFb (xl,330). (C) IgA deposition along the
glomerular capillary walls and in the mesangium (xl ,390). (D) XFb deposition on the same glomerulus (Xl ,390).
activated in the kidneys of these patients. Extensive glomerular
deposits of FRA, not XFb, which were found in some patients
with the above diseases, were probably due to nonspecific
trapping of plasma fibrinogen to glomerular capillary walls or
the mesangium. Since fibrinogen has a low iso-electric point (p1
5.5) [351, electrostatic binding might be responsible for these
deposits. Studies by Melvin, Kim and Michael [36] have shown
that circulating anionic plasma proteins, such as IgG4 (p1 5.5 to
6.0) and albumin (p1 4.9), bind to positively charged moieties
(probably, type IV collagen) of the glomerular basement mem-
brane. Loss of glomerular anionic charge sites in the proteinuric
state [37] could accelerate the binding of fibrinogen to the
glomerular capillary walls.
Since FRA detected by polyclonal antibodies is not sufficient
evidence of activated coagulation [15, 16], platelets and coagu-
lation factors have been studied in human kidneys by several
groups [4—6, 8, 10]. Platelet antigen(s) within damaged glomeruli
has been demonstrated by immunofluorescence in patients with
microangiopathies, diabetes and MPGN [4], and in patients
with severe forms of glomerulonephritis (focal glomeruloscler-
osis, membranous nephropathy and lupus nephritis) [5]. A
marked dissociation between FRA and platelet antigen was
found at the crescents of patients with anti-glomerular base-
ment membrane nephritis, and in the mesangial area of patients
with HSPN [4]. Hoyer, Michael and Hoyer [6], who studied the
relationship between glomerular FRA and factor VIII deposi-
tion, observed clear dissociation in the crescents of patients
with severe proliferative glomerulonephritis, and in the glomer-
uli of patients with HSPN and focal glomerulonephritis. We
observed that glomerular XFb deposition was generally disso-
ciated with platelet membrane antigen or vWf:Ag deposition,
which suggests that fibrin formation in the glomeruli may occur
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Fig. 4. Ultrastructural observation of the glomerulus in a patient with Henoch—SchOnlein purpura nephritis. (A) Immunoelectron microscopy with
indirect peroxidase staining for XFb. Reaction products are present beneath the endothelial cell (arrow) and within the mesangial matrix (x9,750).
(B) Transmission electron microscopy. Electron dense deposits are located in the subendothelial space (arrow) and the mesangium, showing the
similar distribution to XFb (x9,000). Abbreviations are: CL, capillary lumen; En, endothelial cell; Ep, epithelial cell; MM, mesangial matrix.
Fig. 5. Photographs of immune
cells infiltrating glomeruli (G). (A)
Monocytes/macrophages identified
by Mo2 in the glomerulus of a
patient with IgA nephropathy
(x925). (B) Polymorphonuclear cells
identified by anti-lactoferrin in the
glomerulus of a patient with acute
poststreptococcal glomerulonephritis
(x960). Nuclear staining with
ethidium bromide was not applied to
these sections. Arrows denote
Bowman's capsule.
without platelet or factor VIII involvement, or alternatively that
local fibrinolysis may be impaired in comparison with the
clearance mechanism for platelets and factor VIII.
We examined whether XFb is associated with immune com-
plexes or electron dense deposits in the kidney tissues of
patients with IgA nephropathy and HSPN. By dual—staining,
subendothelial deposition of XFb with IgA alone, or IgA and
IgG was observed in about half of the patients. This co-
deposition was occasionally accompanied by C3. On immuno-
electron microscopy to localize XFb, the reaction products with
peroxidase were present beneath the glomerular endothelial cell
and within the mesangial matrix; the distribution was similar to
that of electron dense deposits found on conventional transmis-
sion electron microscopy. Taken together, these observations
suggest that in a certain stage of the above diseases, fibrin
formation is closely related to the immune complex deposition,
and that XFb is one of the constituents of the electron dense
deposits. One possible mechanism for the above findings is that
complements activated by the antigen—antibody complex dam-
age the glomerular basement membrane and expose the
collagen to the circulation, which results in fibnn formation via
factor XII activation and triggering of the clotting pathways.
Another possibility is that endothelial injury due to immune
complexes, antigens, viruses or endotoxins leads to the forma-
tion of fibrin thrombi. Recent studies have indicated that the
endothelial cell can play an active role in preventing the
activation of the coagulation system [38—42]. Anticoagulant
herapin—like molecules [38], thrombomodulin (a cofactor for
activation of the protein C anticoagulant pathway) [39],
plasminogen activator [40] and prostacyclin [41] are expressed
on the endothelial cell surface. Perturbed endothelial cells are
capable of localizing coagulation factors and promoting activa-
tion of the coagulation system up to fibrin formation [42].
Kincaid—Smith [21 suggested, based on the morphological
Monocytes/Macrophages
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observations of human damaged kidneys, that the fibrin deposit
is closely associated with injury involving endothelial cell and
subendothelial areas. Fibrin deposition has long been viewed as
a ubiquitous, but passive, characteristic of the inflammatory
process. Recent studies [43—45], however, have indicated that
fibrin has biological activity, especially for the endothelial cells.
Fibrin—endothelial cell interactions are supported by in vivo and
in vitro experiments. XFb [43], its degradation products [44],
and the fibrinopeptides released during the blood clotting [45]
have been shown to have the potential to induce endothelial cell
injury, such as cell retraction, which mediates the increase of
vascular permeability. Fibrin formation in the kidney might
cause the impairment of glomerular endothelial integrity, and
accelerate the entrapment of immune complexes to the suben-
dothelial space or the mesangial zone. It is possible that the
three phenomena, immune complex deposition, fibrin formation
and endothelial cell injury, form a vicious circle.
There is some evidence that monocytes/macrophages are
responsible for glomerular fibrin formation [3, 46—48]. In exper-
imental nephritis, macrophage depletion prevents both
macrophage accumulation and FRA deposition within the
glomeruli, while animals without macrophage depletion develop
proliferative lesions with heavy FRA deposits [47]. This con-
cept is mainly based on animal studies, and evidence from the
human kidney disease is lacking [3, 48]. In the present studies,
there was no significant difference in the glomerular population
of macrophages between the patients with glomerular XFb
deposition and those without deposition either in the patients
with any disease such as IgA nephropathy or HSPN, which
failed to support the above theory. More macrophages infil-
trated the glomeruli in patients with IgA nephropathy and
HSPN than in those with mesangial proliferative (non-IgA)
glomerulonephritis, and XFb deposition was more frequently
observed in the cases of IgA nephropathy and HSPN. The
possibility that the fibrin deposits we found on the renal tissues
are chronologically dissociated with infiltration of macrophages
could not be excluded. The monoclonal antibody we used in
this study to identify the macrophages reacts with both resting
and activated macrophages [19]. Further study with a marker
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for activated macrophages might be necessary, because macro-
phages express procoagulant activity after being stimulated by
antigens, immune complexes, viruses or lipopolysaccharides
[49].
The potential role of neutrophiles in the pathologic activation
of coagulation has been suggested. Proteases released from
neutrophiles are capable of cleaving prothrombin, fibrinogen, or
other coagulation factors [50, 51]. Our findings do not support
this theory, because the glomerular population of PMN was
small in IgA nephropathy and HSPN, and similar in the patients
with and without XFb deposition.
Elevated urinary excretion of FRA is thought to be due to
intraglomerular fibrin lysis as well as poor protein selectivity
[14, 52, 53]. The same mechanisms seem to be responsible for
the appearance of XFb derivatives in the urine, because we
found that urinary excretion of XFb derivatives was indepen-
dent of intraglomerular XFb deposition. In addition, our studies
show that determination of urinary XFb derivatives is not
satisfactory for the estimation of glomerular fibrin deposition.
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